Studies have demonstrated that JQ1 treatment induces p21, contributing to its anti-leukemic activity in acute myeloid leukemia (AML) cells (55), and causes growth arrest and apoptosis in triple-negative breast cancer, where p21 plays a role in cell cycle arrest (56). The gene discussed is CDKN1A; the disease is triple-negative breast carcinoma.